Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer

Background Modufolin® ([6R]-5,10-methylene tetrahydrofolate; [6R]-MTHF) is an endogenous biomodulator that is being developed as an alternative to leucovorin, a folate prodrug used in the treatment of colorectal cancer. The objective of this phase 1 dose de-escalation trial was to estimate the minim...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Invest New Drugs
Hlavní autoři: Gustavsson, Bengt, Carlsson, Göran, Swartling, Torbjörn, Kurlberg, Göran, Derwinger, Kristoffer, Björkqvist, Hillevi, Odin, Elisabeth, Gibson, Fernando
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer US 2015
Témata:
Phase I Studies
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4768212/
https://ncbi.nlm.nih.gov/pubmed/26189513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-015-0272-0
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky